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ABSTRACT 
 
Background: Brain volume loss (BVL) is a key outcome in MS trials. Natalizumab is highly 
effective on inflammation with moderate impact on atrophy. 
Objective: To explore  BVL in patients receiving natalizumab with an emphasis on grey 
matter (GM). 
Methods: We performed a retrospective post-hoc analysis of BVL in 38 patients receiving 
natalizumab for 3 years  using longitudinal Voxel-Based-Morphometry (VBM) and 
Freesurfer. 
Results: Significant BVL was observed during first year: Brain-Parenchymal-Fraction (BPF): 
-1.12% (p<0.001); White-Matter-Fraction (WMF): -0.9% (p=0.001); Grey-Matter-Fraction 
(GMF): -1.28% (p=0.002). GM loss was found using VBM in bilateral cerebellum, cingulum, 
left>right fronto-parietal cortex, right>left hippocampus, and left caudate. Freesurfer showed 
significant volume losses in subcortical GM, brainstem, and cerebellum, and cortical thinning 
in the left insula. In the second year only WMF decrease (-0.6%; p=0.015) was observed 
with no VBM changes, although Freesurfer, detected significant volume loss in thalamus, 
hippocampus and cerebellum. Baseline gadolinium-enhancement influenced WMF and BPF 
changes during the first year, but not GMF. Patients with confirmed EDSS worsening at 3 
years had lower baseline GMF and left thalamus volume, and greater BVL over follow-up. 
Conclusion: BVL develops mainly during the first year of natalizumab therapy. GM changes 
are independent of baseline inflammation and correlate with disability. 
. 
 
 
 
  
 INTRODUCTION 
Magnetic Resonance Imaging (MRI) is the main paraclinical tool for diagnosis, prognosis 
and monitoring treatment response in Multiple Sclerosis (MS), and a key outcome measure 
in clinical trials1. MRI provides indications on demyelinating, inflammatory and 
neurodegenerative processes2, and it can be used as surrogate for clinical events3. MRI-
derived brain volume loss (BVL) can be used as a marker of neurodegeneration, is detected 
in the early stages of the disease4, 5 and is associated with long term disability6. Grey matter 
(GM) damage, a key component of neurodegeneration7, has also shown significant 
associations with disability8-10. 
Clinical trials have reported positive effects on BVL of some drugs but not others11 and a 
recent meta-analysis showed an additive effect of BVL on active T2 lesions to predict the 
impact of treatment on disability progression at 2 years12. 
Natalizumab has a potent anti-inflammatory effect13, 14 but its impact on neurodegeneration 
outcomes, such as BVL, has not been convincingly shown13,15, probably due to a 
pseudoatrophy effect mostly affecting white matter (WM)16.Thus, to better delineate the 
impact of natalizumab on neurodegeneration, the investigation of GM volume and its 
correlation with clinical outcomes such as disability is warranted. 
The present study aims to explore longitudinal global and regional brain volume changes in 
MS patients receiving natalizumab for at least 36 months. Cortical and subcortical GM 
volumes and Cortical Thickness (CTh) were determined with the FreeSurfer software and 
the Voxel Based Morphometry (VBM) approach implemented in the Statistical Parametric 
Mapping (SPM) software was used. A description of such changes will be complemented 
with clinical and radiological correlations, with an emphasis on disability progression.  
 
 
  
METHODS 
Clinical Data 
A consecutive cohort of MS patients receiving natalizumab 300mg IV every four weeks for at 
least 36 consecutive months as of December 2013 was selected. Clinical assessments were 
performed three-monthly by a trained neurologist including MS relapses, progressive 
multifocal leukoencephalopathy symptoms and EDSS. Confirmed EDSS worsening was 
defined as an increase of 1 point when baseline EDSS <5.5 or an increase of 0.5 point if 
baseline EDSS >5.5, sustained up until the 36 month follow-up time-point.  
The study was approved by the local ethics committee and the patients signed an informed 
consent. 
 
MRI Data 
MRI Acquisition 
Patients underwent MRI within three months of natalizumab initiation (baseline) and at 12, 
24 and 36 months of follow-up. Images were acquired in a 1.5T scanner (Siemens 
Symphony, Erlangen, Germany) using an MS protocol including: pre- and post-gadolinium 
(Gd) T1-weighted (2D-T1) and Magnetization-Prepared Rapid Acquisition Gradient Echo 
(MPRAGE) images. (MRI Appendix). 
 
WM lesion delineation and MPRAGE masking 
Hypointense lesions on 2D-T1 images were visually identified and marked-off by a trained 
neurologist using a semi-automated edge-finding tool (Jim Version 6.0, Xinapse Systems, 
Northants, UK; http://www.xinapse.com). Binary lesion-masks for each patient were created 
using JIM6 and the lesion volume (LV) was calculated. 2D-T1 images (and corresponding 
lesion masks) were co-registered, to the MPRAGE using SPM (SPM8, Wellcome 
Department of Cognitive Neurology, London, UK, http://www.fil.ion.ucl.ac.uk/spm). The co-
registered lesion-masks were visually checked for errors and used in the segmentation step 
to prevent misclassification of WM lesions in the MPRAGE images.  
 VBM: Longitudinal processing 
Longitudinal processing stream implemented in VBM8 was used for assessing GM changes 
between time points. Briefly, all images of each subject were co-registered to correct for 
differences in position and distribution of intensity non-uniformities. Spatial normalization 
parameters were estimated for the baseline image only and applied to all images17. 
Segmentation of GM, WM, cerebrospinal fluid -CSF-, lesion masks, and modulation were 
performed. Finally, smoothing using a 10mm full width at half maximum Gaussian kernel 
was performed prior to statistics. Global, tissue-specific volumes as well as the 
corresponding fractions (GMF=GM/TIV, WMF=(WM+LV)/TIV, BPF=(GM+WM+LV)/TIV) were 
also obtained. The percentage of GMF, WMF and BPF change between time points was 
derived from the following formula: 
100*[TissueFraction(Timepoint1)-TissueFraction(Timepoint2)/TissueFraction(Timepoint1)]) 
 
FreeSurfer 
Global and regional CTh as well as cortical and subcortical GM volume measures were 
obtained at baseline, 12, 24 and 36 months of follow-up on the MPRAGE images by means 
of the longitudinal stream17 included in the FreeSurfer analysis suite (release v5.1.0, 
http://surfer.nmr.mgh.harvard.edu/). FreeSurfer estimated regional volumes were normalized 
for estimated TIV. Mean CTh measures for each lobe were calculated as the sum of the 
thickness of individual cortices included in each lobe, divided by the number of cortices 
included. The percentage of regional volume/CTh change between time points was 
calculated as mentioned above in the VBM section. WM structures were not included in this 
study. 
 
 
Statistical Analysis 
VBM- and FreeSurfer-derived global and tissue-specific volumes 
After checking for normality of data distribution, associations between baseline clinical 
variables, discrete tissue fractions values (GMF, WMF, BPF), FreeSurfer regional GM 
volumes (cortical, subcortical) and mean lobar CTh were tested. Bivariate correlations were 
evaluated using the Pearson or the Spearman rank correlation coefficients. Partial 
correlations were assessed using covariates of interest. A t-test for paired samples was used 
to search for differences of GMF/WMF/BPF in each pair of consecutive time points and a t-
test for independent samples was used to check differences between groups. Statistical 
significance was set at p<0.05.  Given the exploratory nature of the study and the use of 
discrete data, significance values are reported without correction for multiple comparisons to 
avoid type II errors. Statistical Package for the Social Sciences (SPSS, Version 21, Chicago, 
Illinois, USA) and Graphpad Prism5 (Graphpad Software Inc. www.graphpad.com) were 
used. 
 
VBM Analysis 
We evaluated regional baseline GM differences between groups for gender (male vs. 
female), and presence of Gd-enhancement (Gd- vs. Gd+), using a two-sample t-test model, 
and correlations with demographic and clinical data (age, disease duration (DD), baseline 
EDSS and EDSS at last visit) using a Multiple Regression Model. Longitudinal regional GM 
changes between time points were assessed using a Flexible Factorial Design19, including 
age and DD as covariates. Differences were considered significant at p<0.05and k=10 
voxels. We have used the FWE-corrected p value to avoid false positives. For each 
correlation both direct and inverse contrasts were probed. The localization of areas of GM 
atrophy was defined using the Anatomic Automatic Labelling20 tool from SPM8. To evaluate 
differences in GM changes between groups we produced a “difference image” using SPM8, 
subtracting the smoothed images between time points, and comparing the differences 
between groups (two-sample t-test model) or the association with an explanatory variable 
(Multiple Regression Model) as appropriate. 
 
  
RESULTS 
 
Sample selection and composition 
 
A total of 74 patients receiving natalizumab for at least 36 consecutive months were 
identified, 38 had MRI scans that were suitable for VBM and FreeSurfer analysis at baseline, 
37 at month 12 (1 excluded scan because it was acquired in a different scanner), 32 at 
month 24 (6 excluded scans because they were acquired in a different scanner) and 20 at 
month 36 (18 excluded scans because they were acquired in a different scanner). Six 
patients (15.8%) experienced confirmed EDSS worsening at 36 months. Baseline 
characteristics of included and excluded patients are shown in Table 1. 
 
Baseline cross-sectional analysis 
 
VBM-derived global and tissue-specific volumes 
Older age at baseline was correlated with a lower GMF (r=-0.631, p<0.001; adjusting for DD 
partial r=-0.608, p=0.009). No significant correlations of age with WMF (r=0.158, p=0.34) or 
BPF (r=-0.288, p=0.79) were observed. No differences in global or tissue-specific fractions 
were observed between male and female patients (mean GMF 0.466 vs. 0.469, p=0.64; 
WMF 0.333 vs. 0.331, p=0.78; BPF 0.799 vs. 0.800, p=0.92). Longer DD was associated 
with lower global and tissue-specific fractions: GMF (r=-0.387, p=0.01), WMF (r=-0.315, 
p=0.054), and BPF (r=-0.501, p=0.001), but only GMF remained statistically significant after 
adjusting for age (partial r=-0.36, p=0.045). Higher baseline EDSS scores were associated 
with a lower GMF (Rho=-0.312, p=0.028), BPF (Rho=-0.269, p=0.051), but no correlations 
were observed between EDSS and WMF (Rho=-0.089, p=0.29). We found no differences in 
baseline global or tissue-specific fractions between patients with or without Gd-enhancement 
at baseline (mean GMF 0.471 vs. 0.464, p=0.31; WMF 0.329 vs. 0.335, p=0.41; BPF 0.800 
vs. 0.800 p=0.98). 
 
VBM-derived analysis 
We only found a significant association between age and GM concentration in the right 
supramarginal gyrus (T=6.77, MNI coordinates (48,-34,4) p<0.005) (older age implies lower 
GM concentration). No statistically significant regional GM differences were observed for 
other variables. 
 
FreeSurfer-derived parameters 
Cortical, subcortical and cerebellar volumes. Significant negative correlations were observed 
between age and left hippocampal and amygdalar volumes, as well as with bilateral cortical 
volumes, although these correlations did not persist after adjusting for DD. DD was found to 
negatively correlate with bilateral cortical and subcortical GM volumes, and with a number of 
individual subcortical structures. Baseline EDSS was also negatively correlated with bilateral 
cortical and subcortical GM volumes and with bilateral cerebellar cortical volume, as well as 
with a number of individual subcortical structures (Table 2). 
 
Cortical Thickness measures. Age was correlated with left mean hemispheric CTh, 
especially with left insular and left frontal CTh which survived after adjusting for DD. DD was 
correlated with bilateral mean CTh, especially within the parietal and occipital lobes. No 
significant correlations were observed with baseline EDSS (Table 2). 
 
Longitudinal analysis: description of changes in brain fractions and regional GM 
 
VBM-derived global and tissue-specific volumes 
Statistically significant decreases were observed during the first year in GMF (-1.28%, 
p=0.002), WMF (-0.9%, p=0.001) and BPF (-1.125%, p<0.001). During the second year, only 
a significant WMF loss was observed (-0.6%, p=0.015; GMF -0.43%, p=0.4; BPF -0.62%, 
p=0.17) (Figure 1). 
 
VBM-derived analysis 
Areas of significant GM decrease after 12 months were located in bilateral cerebellum, 
bilateral cingulum, left>right parietal-frontal cortex, right>left hippocampus, and left caudate 
(Table 3, Figure 2). No further changes were observed in years 2 and 3. 
 
 
FreeSurfer-derived parameters 
Cortical, subcortical and cerebellar volumes. Significant volume decreases during the first 
year were found in the brainstem, in a number of subcortical GM structures and the 
cerebellum bilaterally, and in the left hemisphere cortex. During the second year, we only 
found significant decreases in the left thalamus, and bilaterally in the cerebellar cortex and 
hippocampus. During the third year, only a significant decrease within the cerebellar cortex 
was found bilaterally (Table 4). 
 
Cortical thickness measures. Only a significant decrease was observed within the left insula 
during the first year of treatment (p=0.024). No further changes were observed in years 2 
and 3. 
 
Longitudinal analysis: correlations. 
 
VBM-derived global and tissue-specific volumes 
Age, gender and baseline EDSS were not correlated with changes in any tissue-specific 
fraction for any of the three one-year periods. Patients with Gd-enhancement at baseline had 
greater WMF losses during the first year (mean WMF change: Gd- -0.09% vs. Gd+ -1.77%, 
p=0.002) whereas no differences were found for GMF (mean GMF change: Gd- -0.9% vs. 
Gd+ -1.2%, p=0.59); a trend was observed for BPF (mean BPF change: Gd- -0.5% vs. Gd+ -
1.4%, p=0.057). No differences between Gd- and Gd+ groups were observed for any fraction 
in the second or third year of follow-up. Patients with confirmed EDSS worsening had lower 
baseline GMF (worsening EDSS: 0.451 vs. stable/improved EDSS: 0.471, p=0.025) and 
higher baseline WMF (worsening: 0.354 vs. stable/improved: 0.328, p=0.012), whereas no 
differences were found in baseline BPF (p=0.64). Patients with confirmed EDSS worsening 
had greater GMF loss (mean change -1.97% vs. 0.42%, p=0.012) and BPF loss (mean 
change -1.26% vs. 0.19%, p= 0.02) during the third year (Figure 3). 
 
VBM-derived analysis 
No statistically significant associations were observed between regional GM changes and 
baseline clinical variables, baseline Gd-enhancement or EDSS change status. 
 
FreeSurfer-derived parameters 
Cortical, subcortical and cerebellar volumes. Male patients had greater left cerebellar cortex 
volume loss during the first year (-2.3% vs -0.73%, p=0.025) but no other significant 
associations with regional volume changes were observed; age and Gd status at baseline 
were not associated with any FreeSurfer-derived regional volume changes in any of the 
three one-year periods. Patients who experienced confirmed EDSS worsening had smaller 
baseline left thalamus volume (0.395 vs 0.443, p=0.037) and larger volume losses during the 
first year in left pallidum (-12.5% vs -4.4%, p=0.055), bilateral cortical (-3.18% vs -0.19%, 
p=0.014), and total GM (-3.0% vs -0.51%, p=0.019). No significant associations were found 
during the second or third one-year periods. 
Cortical thickness measures. No CTh changes in any of the three one-year periods were 
found to be significantly correlated with gender, age, DD, baseline EDSS or Gd status. 
Patients with confirmed EDSS worsening had larger bilateral mean CTh decreases during 
the first year (-2.18% vs 0.01%, p=0.049). No other significant associations were found. 
  
DISCUSSION 
 
In this study we present a cross-sectional and longitudinal VBM and FreeSurfer study 
describing global and regional GM volume and CTh changes in patients receiving 
natalizumab as a retrospective post hoc analysis in a sub-cohort of patients with 3D-T1 MRI. 
Our results provide evidence that significant whole brain, WM and GM loss (a widespread 
damage which is affecting infratentorial, subcortical and cortical structures) is present during 
the first year of treatment with natalizumab. WM changes are in close relation with Gd-
enhancement at baseline, but this is not the case for GM. It also seems that atrophy slows 
during the second and third year of treatment (but it is still significant for WM, during the 
second year, and cerebellum GM until the third year of treatment). GM changes (but not 
WM) are the only to be significantly associated with clinical parameters (e.g., disability).  
The present findings are also consistent with our two previous reports on the same cohort. In 
a one-year follow-up study using 2D-T1 scans and a segmentation approach we have 
previously shown that early changes in the first year of treatment with natalizumab were 
mainly due to WM volume loss (pseudoatrophy effect) and were influenced by baseline Gd-
enhancement, whereas no significant GM volume changes were found16. In the 3-year 
follow-up study of this same cohort using 2D-T1 images analysed with SIENA, the influence 
of baseline MRI activity in whole BVL was also significant all through the second year, with a 
marginal association of BVL and disability21. Changes in black-hole volume or new T2/Gd+ 
lesions were not significantly correlated with disability progression in this cohort (data not 
shown).  
In the present study we have used a different approach to evaluate regional BVL in a 
subcohort for which 3D-T1 studies were available with a voxel-to-voxel and surface-based 
analysis, to focus on GM volume and CTh changes and their association with disability. 
 
Patterns of regional GM atrophy have been widely described using VBM, both in cross-
sectional22 and longitudinal23 analyses, although a distinctive GM pattern associated with a 
specific stage has not been elucidated yet, probably due to the high heterogeneity of the 
disease. Our findings are in agreement with the areas found by Lansley et al. in a recent 
metanalysis of VBM studies which reported significant GM loss in bilateral thalamus, basal 
ganglia, bilateral pre and post central cortex and cingulum9. FreeSurfer results seem to add 
a more detailed depiction of subcortical GM volume loss during the same period of time.  
These areas are strongly interconnected with other brain regions8 and have also been 
correlated with disability 24,25. 
 
In our cohort, composed mainly of young RRMS patients with moderate disability, VBM 
results showed that only global GM volume was significantly correlated with baseline EDSS. 
Using FreeSurfer, we did find an association between disability and regional GM volumes 
including cortical hemispheric, subcortical and bilateral cerebellum areas, which is in 
agreement with previous studies26 showing that correlations with clinical status are mostly 
involving GM and not WM10.  
 
First year GM atrophy could be theoretically attributed to real neurodegenerative processes 
such as Wallerian and axonal degeneration, in our VBM analysis we found no differences 
during the second or third year, maybe indicating a slowdown of atrophy during this period, 
as previously documented with the use of disease modifying therapies 27,28. Using 
FreeSurfer we were able to find GM loss during the second year in a few restricted areas 
(left thalamus and bilateral hippocampus), while cerebellum cortex volume loss was 
significant all through the 36 months of study, maybe indicating that this software might be 
more sensitive subtle changes. 
 
Although we could not find any particular longitudinal GM region loss associated with 
confirmed EDSS worsening using VBM, probably due to small sample size and small 
proportion of patients who experienced EDSS worsening, it was interesting to note that 
patients who deteriorated had lower baseline GMF than those who remained 
stable/improved, findings that have been reported in previous studies29,30. These patients 
also experienced greater GMF and BPF loss in the third year of follow-up. This is also in line 
with a recent 10 year follow-up study in 81 MS patients showing that patients with disability 
progression developed significantly larger whole brain, cortical and putamen volume loss 
compared to patients without disability, with no differences in WM or lesion volume31. 
Whether the observed stabilization of GM damage is due to a neuroprotective effect of 
natalizumab deserves further investigation in appropriately designed studies. Some studies 
have already pointed to this hypothesis using  MRI32,33 , with recent studies using 
spectroscopy showing that natalizumab increases the levels of N-acetylaspartate, creatine 
and phosphocreatine, maybe indicating an enhanced axonal metabolism in natalizumab-
treated patients34 and reduction of WM damage during the first year of treatment using 
diffusion tensor imaging35. Finally, body fluid biomarkers in a progressive MS study with 
patients treated with natalizumab also showed a reduction in intrathecal inflammation 
(decreased levels of osteopontin) accompanied by decreases in other markers of 
neurodegeneration (neurofilament light chain) and tissue damage (increases in MTR in 
cortical GM and normal-appearing WM)36. Nonetheless, it is worth mentioning that these 
findings cannot be used to predict treatment response to natalizumab and they are, at 
present, only valid for group analyses purposes. 
 
As a small exploratory study with  a retrospective post-hoc analysis, our findings are limited 
by the initial small sample size and posterior longitudinal case attrition due to acquisition in 
different scanners precluding valid comparisons. Enough evidence is available that using 
different scanners in longitudinal analysis may hinder the results, and we decided to exclude 
these images to improve reliability and consistency of the results, at expenses of losing 
sample size37. Also, as we reported the significant values without correction for multiple 
comparisons to avoid type II errors, number of false positives or false negatives could be 
inflated. A control group (healthy controls and/or patients on different disease modifying 
therapy) would have been useful to truly determine the possible impact of natalizumab in the 
suppression of BVL, and particularly GM atrophy observed during the second and third year 
of treatment. Regional correlations with physical disability (eg. MSFC 9HPT, 25FWT or 
Functional Scores), cognitive impairment, fatigue, and quality of life scales would also had 
been interesting to explore. 
 
In conclusion, patients receiving natalizumab develop significant global BVL during the first 
year of treatment. WM volume changes, occurring throughout the first 24 months, are 
influenced by Gd-enhancement at baseline, but GM volume changes, seem to be 
independent of baseline inflammation and appear to be correlated with disability. Further 
prospective studies in larger samples are warranted to investigate whether global or regional 
BVL may be useful to predict treatment response to natalizumab. 
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